Journal article
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction
Expert review of cardiovascular therapy, Vol.4(4), pp.461-476
07/2006
DOI: 10.1586/14779072.4.4.461
PMID: 16918265
Abstract
A low-density lipoprotein (LDL) cholesterol goal of less than 100 mg/dl is recommended for patients at moderate to high risk of cardiovascular disease with an optional LDL goal of less than 70 mg/dl for patients at a very high risk of cardiovascular disease. Most patients will require reductions in LDL of more than 50% in order to achieve these more aggressive goals. Only a few agents will lower LDL by at least 50%. This review will focus on the efficacy and safety ezetimibe/simvastatin coadministered as a therapy with enhanced LDL-lowering efficacy, while minimizing the adverse effects of statins in a wide range of patients. Ezetimibe 10 mg/simvastatin 80 mg lowers LDL by approximately 60% and has been demonstrated to be superior to the highest doses of atorvastatin and rosuvastatin for lowering LDL and raising high-density lipoprotein.
Details
- Title: Subtitle
- Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction
- Creators
- Jennifer G Robinson - University of Iowa, Lipid Research Clinic, Departments of Epidemiology & Medicine, 200 Hawkins Drive, SE 226 GH, Iowa City, IA 52242, USA. jennifer-g-robinson@uiowa.eduMichael H Davidson
- Resource Type
- Journal article
- Publication Details
- Expert review of cardiovascular therapy, Vol.4(4), pp.461-476
- DOI
- 10.1586/14779072.4.4.461
- PMID
- 16918265
- NLM abbreviation
- Expert Rev Cardiovasc Ther
- eISSN
- 1744-8344
- Publisher
- England
- Language
- English
- Date published
- 07/2006
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995152002771
Metrics
22 Record Views